Search

everythinglearnresearchcommunity

for

Search:↓

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.

Scientists found gene mutations that affect hair loss, skin stem cells, and skin disorders, and identified drugs that may help treat blood vessel and skin conditions.

FTY720 helps transplanted fat survive better by reducing immune rejection and improving blood vessel growth.

AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

Tofacitinib taken by mouth helps treat hair loss in children.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

High levels of ODC and a mutant Ha-ras gene cause tumors in mice.

A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

TYK2 inhibitors show promise for treating cancer and autoimmune disorders.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Peptide nanoparticles can effectively deliver CRISPR-Cas9 to target KRAS mutations in cancer.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.

Tofacitinib helped regrow hair in a woman with alopecia areata.

Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.